Mesothelioma Treatment Timeline - Revision history

MesotheliomaSupport: Internal linking: added 3 wiki links

2026-02-20T20:57:37Z

Internal linking: added 3 wiki links

← Older revision		Revision as of 20:57, 20 February 2026
Line 36:		Line 36:
	== Executive Summary ==		== Executive Summary ==

	The history of mesothelioma treatment spans more than 250 years, from the first documented cases in 1767 to the immunotherapy revolution of 2020 and the emerging therapies of today.<ref>[https://dandell.com/malignant-mesothelioma/ Malignant Mesothelioma Lawyers], Danziger & De Llano</ref> This timeline traces the key milestones that transformed mesothelioma from an unknown pathological curiosity into a treatable—though still challenging—disease. Major breakthroughs include [[J_Christopher_Wagner\|J. Christopher Wagner's]] 1960 proof that asbestos causes mesothelioma, the 2004 FDA approval of pemetrexed chemotherapy, and [[Dr_Paul_Baas\|Dr. Paul Baas's]] [[CheckMate_743_Trial\|CheckMate 743 trial]] that established immunotherapy as the new standard of care in 2020.<ref>[https://mesothelioma.net/immunotherapy/ Immunotherapy for Mesothelioma], Mesothelioma.net</ref> Understanding this history helps patients and families appreciate both how far treatment has come and the ongoing research that promises even better outcomes in the future.<ref>[https://www.mesotheliomalawyercenter.org/blog/first-new-approved-treatment-for-mesothelioma-in-more-than-a-decade/ First New Approved Treatment for Mesothelioma], Mesothelioma Lawyer Center</ref>		The history of [[Mesothelioma\|mesothelioma]] treatment spans more than 250 years, from the first documented cases in 1767 to the immunotherapy revolution of 2020 and the emerging therapies of today.<ref>[https://dandell.com/malignant-mesothelioma/ Malignant Mesothelioma Lawyers], Danziger & De Llano</ref> This timeline traces the key milestones that transformed mesothelioma from an unknown pathological curiosity into a treatable—though still challenging—disease. Major breakthroughs include [[J_Christopher_Wagner\|J. Christopher Wagner's]] 1960 proof that asbestos causes mesothelioma, the 2004 FDA approval of pemetrexed chemotherapy, and [[Dr_Paul_Baas\|Dr. Paul Baas's]] [[CheckMate_743_Trial\|CheckMate 743 trial]] that established immunotherapy as the new standard of care in 2020.<ref>[https://mesothelioma.net/immunotherapy/ Immunotherapy for Mesothelioma], Mesothelioma.net</ref> Understanding this history helps patients and families appreciate both how far treatment has come and the ongoing research that promises even better outcomes in the future.<ref>[https://www.mesotheliomalawyercenter.org/blog/first-new-approved-treatment-for-mesothelioma-in-more-than-a-decade/ First New Approved Treatment for Mesothelioma], Mesothelioma Lawyer Center</ref>

	== Key Facts ==		== Key Facts ==
Line 172:		Line 172:
	\| style="padding:10px; font-weight:bold;" \| Late 1990s		\| style="padding:10px; font-weight:bold;" \| Late 1990s
	\| style="padding:10px;" \| [[Dr_Paul_H_Sugarbaker\|Dr. Paul H. Sugarbaker]] develops HIPEC		\| style="padding:10px;" \| [[Dr_Paul_H_Sugarbaker\|Dr. Paul H. Sugarbaker]] develops HIPEC
	\| style="padding:10px;" \| Peritoneal mesothelioma treatment		\| style="padding:10px;" \| [[Peritoneal Mesothelioma\|Peritoneal mesothelioma]] treatment
	\|-		\|-
	\| style="padding:10px; font-weight:bold; " \| 2002		\| style="padding:10px; font-weight:bold; " \| 2002
Line 347:		Line 347:
	== Get Help Today ==		== Get Help Today ==

	If you or a loved one has been diagnosed with mesothelioma, accessing the latest treatments—the result of more than 250 years of scientific progress—can significantly impact survival and quality of life. You may also be entitled to compensation from the companies responsible for your asbestos exposure.<ref>[https://dandell.com/whats-your-case-worth/ What's Your Mesothelioma Case Worth?], Danziger & De Llano</ref>		If you or a loved one has been diagnosed with mesothelioma, accessing the latest treatments—the result of more than 250 years of scientific progress—can significantly impact survival and quality of life. You may also be entitled to compensation from the companies responsible for your [[Asbestos Exposure\|asbestos exposure]].<ref>[https://dandell.com/whats-your-case-worth/ What's Your Mesothelioma Case Worth?], Danziger & De Llano</ref>

	The experienced mesothelioma attorneys at Danziger & De Llano have helped thousands of families navigate both the medical and legal challenges of this diagnosis.		The experienced mesothelioma attorneys at Danziger & De Llano have helped thousands of families navigate both the medical and legal challenges of this diagnosis.

MesotheliomaSupport: Internal linking: added 7 wiki links

2026-02-20T20:54:40Z

Internal linking: added 7 wiki links

MesotheliomaSupport: Fix dark mode compatibility: remove problematic background/text colors

2026-01-29T14:29:12Z

Fix dark mode compatibility: remove problematic background/text colors

Show changes

MesotheliomaSupport: Fix dark mode styling

2026-01-29T03:01:09Z

Fix dark mode styling

MesotheliomaSupport: Bot edit

2026-01-29T00:12:12Z

Bot edit

← Older revision		Revision as of 00:12, 29 January 2026
Line 231:		Line 231:
	\| style="padding:10px; font-weight:bold; background:#d4edda;" \| Oct 2, 2020		\| style="padding:10px; font-weight:bold; background:#d4edda;" \| Oct 2, 2020
	\| style="padding:10px; background:#d4edda;" \| '''FDA approves nivolumab + ipilimumab ([[CheckMate_743_Trial\|CheckMate 743]])'''		\| style="padding:10px; background:#d4edda;" \| '''FDA approves nivolumab + ipilimumab ([[CheckMate_743_Trial\|CheckMate 743]])'''
	\| style="padding:10px; background:#d4edda;" \| '''First immunotherapy for mesothelioma'''		\| style="padding:10px; background:#d4edda;" \| '''First immunotherapy for mesothelioma<ref>[https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-and-ipilimumab-unresectable-malignant-pleural-mesothelioma FDA Approves Nivolumab and Ipilimumab for Mesothelioma], U.S. Food and Drug Administration</ref>'''
	\|-		\|-
	\| style="padding:10px; font-weight:bold;" \| Jan 2021		\| style="padding:10px; font-weight:bold;" \| Jan 2021
Line 281:		Line 281:
	\|-		\|-
	\| style="padding:10px;" \| '''CAR-T Cell Therapy'''		\| style="padding:10px;" \| '''CAR-T Cell Therapy'''
	\| style="padding:10px;" \| Multiple trials ongoing		\| style="padding:10px;" \| Multiple trials ongoing<ref>[https://clinicaltrials.gov/search?cond=Mesothelioma&aggFilters=status:rec Mesothelioma Clinical Trials - Recruiting], ClinicalTrials.gov</ref>
	\| style="padding:10px;" \| Targeted cell-based treatment		\| style="padding:10px;" \| Targeted cell-based treatment
	\|-		\|-
Line 305:		Line 305:
	\|}		\|}

	== Survival Progress Over Time ==		== Survival Progress Over Time

			Treatment advances have progressively improved survival for mesothelioma patients, as documented by national cancer statistics.<ref>[https://seer.cancer.gov/statfacts/html/meso.html Cancer Stat Facts: Mesothelioma], NCI SEER Program</ref> ==

	Treatment advances have progressively improved survival for mesothelioma patients.<ref>[https://dandell.com/mesothelioma-diagnosis/ Mesothelioma Diagnosis Guide], Danziger & De Llano</ref>		Treatment advances have progressively improved survival for mesothelioma patients.<ref>[https://dandell.com/mesothelioma-diagnosis/ Mesothelioma Diagnosis Guide], Danziger & De Llano</ref>

MesotheliomaSupport: Create Mesothelioma Treatment Timeline page

2026-01-28T21:54:11Z

Create Mesothelioma Treatment Timeline page

New page

{{#seo:
|title=Mesothelioma Treatment Timeline: 250 Years of Progress (1767-2025)
|description=Comprehensive timeline of mesothelioma research milestones from 1767 discovery through 2020 immunotherapy approval to current CAR-T and gene therapy research.
|keywords=mesothelioma timeline, mesothelioma history, asbestos cancer history, CheckMate 743, FDA approval mesothelioma, mesothelioma research milestones
|image=mesothelioma-treatment-timeline.jpg
|author=Danziger & De Llano Legal Team
|published_time=2026-01-28
}}
{| class="infobox" style="width:280px; float:right; margin:0 0 1em 1em; border:2px solid #1a5276; background:#ffffff; border-radius:8px; overflow:hidden;"
|-
! colspan="2" style="background:#1a5276; color:white; padding:12px; font-size:1.1em; text-align:center;" | Mesothelioma Timeline at a Glance
|-
| colspan="2" style="background:#e8f4f8; padding:10px; text-align:center; font-style:italic;" | 250+ Years of Scientific Progress
|-
| style="padding:10px; font-weight:bold; width:40%; background:#f8f9fa; border-bottom:1px solid #dee2e6;" | First Cases
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 1767
|-
| style="padding:10px; font-weight:bold; background:#f8f9fa; border-bottom:1px solid #dee2e6;" | Disease Named
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 1909
|-
| style="padding:10px; font-weight:bold; background:#f8f9fa; border-bottom:1px solid #dee2e6;" | Asbestos Link
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 1960
|-
| style="padding:10px; font-weight:bold; background:#f8f9fa; border-bottom:1px solid #dee2e6;" | OSHA Created
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 1970
|-
| style="padding:10px; font-weight:bold; background:#f8f9fa; border-bottom:1px solid #dee2e6;" | First Chemo
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 2004
|-
| style="padding:10px; font-weight:bold; background:#f8f9fa;" | Immunotherapy
| style="padding:10px;" | 2020
|-
| colspan="2" style="background:#1a5276; padding:10px; text-align:center;" | [https://dandell.com/contact-us/ <span style="color:white; font-weight:bold;">Free Case Review →</span>]
|}

== Executive Summary ==

The history of mesothelioma treatment spans more than 250 years, from the first documented cases in 1767 to the immunotherapy revolution of 2020 and the emerging therapies of today.<ref>[https://dandell.com/malignant-mesothelioma/ Malignant Mesothelioma Lawyers], Danziger & De Llano</ref> This timeline traces the key milestones that transformed mesothelioma from an unknown pathological curiosity into a treatable—though still challenging—disease. Major breakthroughs include [[J_Christopher_Wagner|J. Christopher Wagner's]] 1960 proof that asbestos causes mesothelioma, the 2004 FDA approval of pemetrexed chemotherapy, and [[Dr_Paul_Baas|Dr. Paul Baas's]] [[CheckMate_743_Trial|CheckMate 743 trial]] that established immunotherapy as the new standard of care in 2020.<ref>[https://mesothelioma.net/immunotherapy/ Immunotherapy for Mesothelioma], Mesothelioma.net</ref> Understanding this history helps patients and families appreciate both how far treatment has come and the ongoing research that promises even better outcomes in the future.<ref>[https://www.mesotheliomalawyercenter.org/blog/first-new-approved-treatment-for-mesothelioma-in-more-than-a-decade/ First New Approved Treatment for Mesothelioma], Mesothelioma Lawyer Center</ref>

== Key Facts ==

{| class="wikitable" style="width:100%; margin:1em 0; border-collapse:collapse;"
|-
! style="background:#1a5276; color:white; padding:12px; text-align:left;" | Key Facts: Mesothelioma Treatment Milestones
|-
| style="padding:15px; background:#f8f9fa;" |
* '''First Documented Cases:''' 1767 by Joseph Lieutaud (France)
* '''Disease Named "Mesothelioma":''' 1909 by J.G. Adami (UK)
* '''Asbestos-Mesothelioma Link Proven:''' 1960 by J. Christopher Wagner (South Africa)
* '''U.S. Evidence Established:''' 1964 by Dr. Irving Selikoff (Mount Sinai)
* '''OSHA Established:''' 1970 (influenced by Selikoff's research)
* '''First Staging System:''' 1976 by Dr. Eric Butchart
* '''International Mesothelioma Program Founded:''' 2002 by Dr. David Sugarbaker
* '''First FDA-Approved Chemotherapy:''' February 4, 2004 (pemetrexed + cisplatin)
* '''Tumor Treating Fields Approved:''' May 2019 (Optune Lua)
* '''Immunotherapy Approved:''' October 2, 2020 (nivolumab + ipilimumab)
* '''Survival Progress:''' From ~9 months untreated to 18+ months with modern therapy
|}

== Era 1: Discovery and Early Recognition (1767-1959) ==

The earliest chapter of mesothelioma history predates understanding of the disease or its connection to asbestos.<ref>[https://dandell.com/asbestos-exposure/ Asbestos Exposure Lawyers], Danziger & De Llano</ref>

{| class="wikitable" style="width:100%; margin:1em 0;"
|-
! style="background:#1a5276; color:white; padding:10px; width:15%;" | Year
! style="background:#1a5276; color:white; padding:10px;" | Milestone
! style="background:#1a5276; color:white; padding:10px; width:25%;" | Significance
|-
| style="padding:10px; font-weight:bold;" | 1767
| style="padding:10px;" | Joseph Lieutaud documents pleural tumors during autopsies
| style="padding:10px;" | First suspected mesothelioma cases
|-
| style="padding:10px; font-weight:bold;" | 1843
| style="padding:10px;" | Karl von Rokitansky identifies peritoneal tumors
| style="padding:10px;" | Early peritoneal mesothelioma recognition
|-
| style="padding:10px; font-weight:bold;" | 1870
| style="padding:10px;" | E. Wagner describes pleural tumors ("endothelioma")
| style="padding:10px;" | Detailed pathological description
|-
| style="padding:10px; font-weight:bold;" | 1890
| style="padding:10px;" | First documented U.S. mesothelioma case
| style="padding:10px;" | Disease recognized in America
|-
| style="padding:10px; font-weight:bold;" | 1909
| style="padding:10px;" | J.G. Adami coins term "mesothelioma"
| style="padding:10px;" | Disease receives formal name
|-
| style="padding:10px; font-weight:bold;" | 1931
| style="padding:10px;" | Klemperer and Rabin publish seminal paper
| style="padding:10px;" | Distinguished from other pleural tumors
|-
| style="padding:10px; font-weight:bold;" | 1947
| style="padding:10px;" | First case formally recognized as mesothelioma
| style="padding:10px;" | Medical acceptance of diagnosis
|}

{| style="width:100%; background:#cce5ff; border:1px solid #007bff; border-left:5px solid #007bff; border-radius:4px; margin:1em 0;"
|-
| style="padding:15px; color:#004085;" | '''ℹ️ The Missing Link:''' Despite widespread industrial asbestos use during this period, the connection between asbestos exposure and mesothelioma remained unknown. Millions of workers were exposed without any understanding of the deadly consequences.
|}

== Era 2: Establishing Causation (1960-1979) ==

This era saw definitive proof that asbestos causes mesothelioma, leading to the first regulatory protections.<ref>[https://mesothelioma.net/mesothelioma/ Mesothelioma Overview], Mesothelioma.net</ref>

{| class="wikitable" style="width:100%; margin:1em 0;"
|-
! style="background:#1a5276; color:white; padding:10px; width:15%;" | Year
! style="background:#1a5276; color:white; padding:10px;" | Milestone
! style="background:#1a5276; color:white; padding:10px; width:25%;" | Significance
|-
| style="padding:10px; font-weight:bold; background:#d4edda;" | 1960
| style="padding:10px; background:#d4edda;" | '''[[J_Christopher_Wagner|J. Christopher Wagner]] proves asbestos-mesothelioma link'''
| style="padding:10px; background:#d4edda;" | '''Landmark discovery in South Africa'''
|-
| style="padding:10px; font-weight:bold; background:#d4edda;" | 1964
| style="padding:10px; background:#d4edda;" | '''[[Dr_Irving_Selikoff|Dr. Irving Selikoff]] publishes U.S. study'''
| style="padding:10px; background:#d4edda;" | '''6.8x higher mortality in asbestos workers'''
|-
| style="padding:10px; font-weight:bold;" | 1965
| style="padding:10px;" | Selikoff testifies before Congress
| style="padding:10px;" | Influences federal policy
|-
| style="padding:10px; font-weight:bold; background:#d4edda;" | 1970
| style="padding:10px; background:#d4edda;" | '''OSHA established'''
| style="padding:10px; background:#d4edda;" | '''Federal workplace safety agency created'''
|-
| style="padding:10px; font-weight:bold;" | 1972
| style="padding:10px;" | First OSHA asbestos standard
| style="padding:10px;" | Initial exposure limits set
|-
| style="padding:10px; font-weight:bold;" | 1976
| style="padding:10px;" | Dr. Eric Butchart develops first staging system
| style="padding:10px;" | Standardized disease classification
|}

{| style="width:95%; margin:1em auto; background:#f8f9fa; border-left:4px solid #1a5276; border-radius:4px;"
|-
| style="padding:15px 20px 10px; font-style:italic; font-size:1.05em; line-height:1.5;" | "The 1960s represented a turning point in mesothelioma history. Wagner and Selikoff's research proved what asbestos companies had hidden for decades: their products were killing workers. That evidence forms the foundation for the legal cases we pursue today."
|-
| style="padding:5px 25px 20px; text-align:right;" | '''— Paul Danziger,''' Founding Partner, Danziger & De Llano
|}

== Era 3: Surgical Development (1980-2003) ==

Surgeons developed and refined aggressive surgical approaches, establishing multimodal therapy.<ref>[https://dandell.com/mesothelioma-compensation/ Mesothelioma Compensation], Danziger & De Llano</ref>

{| class="wikitable" style="width:100%; margin:1em 0;"
|-
! style="background:#1a5276; color:white; padding:10px; width:15%;" | Year
! style="background:#1a5276; color:white; padding:10px;" | Milestone
! style="background:#1a5276; color:white; padding:10px; width:25%;" | Significance
|-
| style="padding:10px; font-weight:bold;" | 1986
| style="padding:10px;" | EPA proposes asbestos ban
| style="padding:10px;" | Federal action against asbestos
|-
| style="padding:10px; font-weight:bold;" | 1989
| style="padding:10px;" | Asbestos Ban and Phase-Out Rule
| style="padding:10px;" | Partial ban implemented
|-
| style="padding:10px; font-weight:bold;" | 1992
| style="padding:10px;" | [[Dr_David_Sugarbaker|Dr. Sugarbaker]] publishes EPP refinements
| style="padding:10px;" | Improved surgical technique
|-
| style="padding:10px; font-weight:bold;" | 1995
| style="padding:10px;" | IMIG TNM staging system developed
| style="padding:10px;" | International staging standard
|-
| style="padding:10px; font-weight:bold;" | Late 1990s
| style="padding:10px;" | [[Dr_Paul_H_Sugarbaker|Dr. Paul H. Sugarbaker]] develops HIPEC
| style="padding:10px;" | Peritoneal mesothelioma treatment
|-
| style="padding:10px; font-weight:bold; background:#d4edda;" | 2002
| style="padding:10px; background:#d4edda;" | '''International Mesothelioma Program founded'''
| style="padding:10px; background:#d4edda;" | '''World's largest mesothelioma center'''
|}

== Era 4: The Chemotherapy Era (2004-2019) ==

FDA approval of pemetrexed established chemotherapy as standard treatment, though progress remained limited.<ref>[https://mesothelioma.net/treatment-for-mesothelioma/ Mesothelioma Treatment], Mesothelioma.net</ref>

{| class="wikitable" style="width:100%; margin:1em 0;"
|-
! style="background:#1a5276; color:white; padding:10px; width:15%;" | Year
! style="background:#1a5276; color:white; padding:10px;" | Milestone
! style="background:#1a5276; color:white; padding:10px; width:25%;" | Significance
|-
| style="padding:10px; font-weight:bold; background:#d4edda;" | Feb 4, 2004
| style="padding:10px; background:#d4edda;" | '''FDA approves pemetrexed + cisplatin'''
| style="padding:10px; background:#d4edda;" | '''First approved mesothelioma drug'''
|-
| style="padding:10px; font-weight:bold;" | 2011
| style="padding:10px;" | MARS trial published
| style="padding:10px;" | EPP shows no survival benefit
|-
| style="padding:10px; font-weight:bold;" | 2012
| style="padding:10px;" | Moffitt establishes mesothelioma center
| style="padding:10px;" | Major center formalizes program
|-
| style="padding:10px; font-weight:bold;" | 2018
| style="padding:10px;" | [[Dr_David_Sugarbaker|Dr. David Sugarbaker]] passes; [[Dr_Raphael_Bueno|Dr. Bueno]] leads IMP
| style="padding:10px;" | Leadership transition
|-
| style="padding:10px; font-weight:bold;" | 2019
| style="padding:10px;" | INITIATE trial proves dual immunotherapy concept
| style="padding:10px;" | Sets stage for CheckMate 743
|-
| style="padding:10px; font-weight:bold; background:#d4edda;" | May 2019
| style="padding:10px; background:#d4edda;" | '''FDA approves Tumor Treating Fields (Optune Lua)'''
| style="padding:10px; background:#d4edda;" | '''Novel treatment modality'''
|}

{| style="width:100%; background:#fff3cd; border:1px solid #ffc107; border-left:5px solid #ffc107; border-radius:4px; margin:1em 0;"
|-
| style="padding:15px; color:#856404;" | '''⚠️ 16 Years Without Progress:''' From 2004 to 2020, no new systemic therapy was approved for mesothelioma. Patients had essentially one first-line option. This long gap underscores why the 2020 immunotherapy approval was so significant.
|}

== Era 5: The Immunotherapy Revolution (2020-Present) ==

The approval of dual immunotherapy marked the most significant advance in mesothelioma treatment since 2004.<ref>[https://www.mesotheliomalawyercenter.org/blog/first-new-approved-treatment-for-mesothelioma-in-more-than-a-decade/ First New Approved Treatment for Mesothelioma], Mesothelioma Lawyer Center</ref>

{| class="wikitable" style="width:100%; margin:1em 0;"
|-
! style="background:#1a5276; color:white; padding:10px; width:15%;" | Year
! style="background:#1a5276; color:white; padding:10px;" | Milestone
! style="background:#1a5276; color:white; padding:10px; width:25%;" | Significance
|-
| style="padding:10px; font-weight:bold; background:#d4edda;" | Oct 2, 2020
| style="padding:10px; background:#d4edda;" | '''FDA approves nivolumab + ipilimumab ([[CheckMate_743_Trial|CheckMate 743]])'''
| style="padding:10px; background:#d4edda;" | '''First immunotherapy for mesothelioma'''
|-
| style="padding:10px; font-weight:bold;" | Jan 2021
| style="padding:10px;" | CheckMate 743 results published in The Lancet
| style="padding:10px;" | Full trial data available
|-
| style="padding:10px; font-weight:bold;" | 2021
| style="padding:10px;" | European approval of immunotherapy
| style="padding:10px;" | Global standard of care
|-
| style="padding:10px; font-weight:bold;" | 2023
| style="padding:10px;" | [[Dr_Paul_Baas|Dr. Baas]] receives Heine H. Hansen Lifetime Award
| style="padding:10px;" | CheckMate 743 leader honored
|-
| style="padding:10px; font-weight:bold;" | 2023
| style="padding:10px;" | SynKIR-110 CAR-T receives FDA Fast Track
| style="padding:10px;" | Emerging cell therapy
|-
| style="padding:10px; font-weight:bold;" | 2025
| style="padding:10px;" | Johns Hopkins perioperative immunotherapy trial
| style="padding:10px;" | 28.6 months survival reported
|-
| style="padding:10px; font-weight:bold;" | 2025
| style="padding:10px;" | MSK launches CAR-T + anti-PD-1 phase I trial
| style="padding:10px;" | Novel combination approach
|}

{| style="width:100%; background:#d4edda; border:1px solid #28a745; border-left:5px solid #28a745; border-radius:4px; margin:1em 0;"
|-
| style="padding:15px; color:#155724;" | '''✅ Survival Progress:''' The CheckMate 743 trial demonstrated 18.1 months median survival with immunotherapy—a 4-month improvement over chemotherapy. For non-epithelioid patients, survival more than doubled from 8.8 to 18.1 months.
|}

{| style="width:95%; margin:1em auto; background:#f8f9fa; border-left:4px solid #1a5276; border-radius:4px;"
|-
| style="padding:15px 20px 10px; font-style:italic; font-size:1.05em; line-height:1.5;" | "October 2, 2020 was a watershed moment for mesothelioma patients. For the first time in 16 years, we could tell newly diagnosed clients about a fundamentally new treatment option—one that offered real hope, especially for those with non-epithelioid disease who previously had so few options."
|-
| style="padding:5px 25px 20px; text-align:right;" | '''— Rod De Llano,''' Founding Partner, Danziger & De Llano
|}

== Current Research Frontiers (2024-2026) ==

Research continues on multiple fronts, with promising approaches in development.<ref>[https://mesothelioma.net/mesothelioma-emerging-treatments-research/ New Mesothelioma Treatments and Research], Mesothelioma.net</ref>

{| class="wikitable" style="width:100%; margin:1em 0;"
|-
! style="background:#1a5276; color:white; padding:10px;" | Research Area
! style="background:#1a5276; color:white; padding:10px;" | Status
! style="background:#1a5276; color:white; padding:10px;" | Potential Impact
|-
| style="padding:10px;" | '''CAR-T Cell Therapy'''
| style="padding:10px;" | Multiple trials ongoing
| style="padding:10px;" | Targeted cell-based treatment
|-
| style="padding:10px;" | '''Gene Therapy'''
| style="padding:10px;" | Inhalable formulations in development
| style="padding:10px;" | Direct tumor targeting
|-
| style="padding:10px;" | '''TEAD Inhibitors'''
| style="padding:10px;" | Preclinical/early clinical
| style="padding:10px;" | Hippo pathway targeting
|-
| style="padding:10px;" | '''PARP Inhibitors'''
| style="padding:10px;" | NERO trial ongoing
| style="padding:10px;" | For BAP1-mutated tumors
|-
| style="padding:10px;" | '''Perioperative Immunotherapy'''
| style="padding:10px;" | Promising early results
| style="padding:10px;" | 28.6 months survival achieved
|-
| style="padding:10px;" | '''Liquid Biopsy'''
| style="padding:10px;" | ctDNA monitoring validated
| style="padding:10px;" | Early detection, monitoring
|}

== Survival Progress Over Time ==

Treatment advances have progressively improved survival for mesothelioma patients.<ref>[https://dandell.com/mesothelioma-diagnosis/ Mesothelioma Diagnosis Guide], Danziger & De Llano</ref>

{| class="wikitable" style="width:100%; margin:1em 0;"
|-
! style="background:#1a5276; color:white; padding:10px;" | Era
! style="background:#1a5276; color:white; padding:10px;" | Treatment
! style="background:#1a5276; color:white; padding:10px;" | Median Survival
|-
| style="padding:10px;" | Pre-2004
| style="padding:10px;" | Supportive care only
| style="padding:10px;" | ~9 months
|-
| style="padding:10px;" | 2004-2019
| style="padding:10px;" | Pemetrexed + platinum
| style="padding:10px;" | 12-14 months
|-
| style="padding:10px;" | 2020+
| style="padding:10px;" | Nivolumab + ipilimumab
| style="padding:10px;" | 18.1 months
|-
| style="padding:10px;" | Selected patients
| style="padding:10px;" | Trimodal therapy + HIPEC
| style="padding:10px;" | 35.6 months
|-
| style="padding:10px;" | 2025 trial
| style="padding:10px;" | Perioperative immunotherapy
| style="padding:10px;" | 28.6 months
|}

{| style="width:95%; margin:1em auto; background:#f8f9fa; border-left:4px solid #1a5276; border-radius:4px;"
|-
| style="padding:15px 20px 10px; font-style:italic; font-size:1.05em; line-height:1.5;" | "Looking at this timeline, the progress is remarkable. A diagnosis that once meant months to live can now mean years with modern treatment. And the pace of research is accelerating—the breakthroughs of the next decade will likely exceed everything that came before."
|-
| style="padding:5px 25px 20px; text-align:right;" | '''— David Foster,''' Client Advocate, Danziger & De Llano
|}

== Get Help Today ==

If you or a loved one has been diagnosed with mesothelioma, accessing the latest treatments—the result of more than 250 years of scientific progress—can significantly impact survival and quality of life. You may also be entitled to compensation from the companies responsible for your asbestos exposure.<ref>[https://dandell.com/whats-your-case-worth/ What's Your Mesothelioma Case Worth?], Danziger & De Llano</ref>

The experienced mesothelioma attorneys at Danziger & De Llano have helped thousands of families navigate both the medical and legal challenges of this diagnosis.

📞 '''Call (866) 222-9990''' or [https://dandell.com/contact-us/ request a free case review online].

== See Also ==

* [[History_of_Mesothelioma_Research|History of Mesothelioma Research]]
* [[Dr_Paul_Baas|Dr. Paul Baas]]
* [[Dr_Irving_Selikoff|Dr. Irving Selikoff]]
* [[Dr_David_Sugarbaker|Dr. David Sugarbaker]]
* [[CheckMate_743_Trial|CheckMate 743 Trial]]
* [[Clinical_Trials|Clinical Trials]]
* [[Treatment_Options|Treatment Options]]
* [[Mesothelioma_Treatment_Centers|Mesothelioma Treatment Centers]]

== References ==

<references />

[[Category:Mesothelioma Research]]
[[Category:Treatment History]]
[[Category:Mesothelioma]]
[[Category:Clinical Trials]]

← Older revision		Revision as of 20:54, 20 February 2026
Line 9:		Line 9:
	{\| class="infobox" style="width:280px; float:right; margin:0 0 1em 1em; border:2px solid #1a5276; border-radius:8px; overflow:hidden;"		{\| class="infobox" style="width:280px; float:right; margin:0 0 1em 1em; border:2px solid #1a5276; border-radius:8px; overflow:hidden;"
	\|-		\|-
	! colspan="2" style="background:#1a5276; color:white; padding:12px; font-size:1.1em; text-align:center;" \| Mesothelioma Timeline at a Glance		! colspan="2" style="background:#1a5276; color:white; padding:12px; font-size:1.1em; text-align:center;" \| [[Mesothelioma]] Timeline at a Glance
	\|-		\|-
	\| colspan="2" style="padding:10px; text-align:center; font-style:italic;" \| 250+ Years of Scientific Progress		\| colspan="2" style="padding:10px; text-align:center; font-style:italic;" \| 250+ Years of Scientific Progress
Line 47:		Line 47:
	* '''First Documented Cases:''' 1767 by Joseph Lieutaud (France)		* '''First Documented Cases:''' 1767 by Joseph Lieutaud (France)
	* '''Disease Named "Mesothelioma":''' 1909 by J.G. Adami (UK)		* '''Disease Named "Mesothelioma":''' 1909 by J.G. Adami (UK)
	* '''Asbestos-Mesothelioma Link Proven:''' 1960 by J. Christopher Wagner (South Africa)		* '''Asbestos-Mesothelioma Link Proven:''' 1960 by [[J. Christopher Wagner]] (South Africa)
	* '''U.S. Evidence Established:''' 1964 by Dr. Irving Selikoff (Mount Sinai)		* '''U.S. Evidence Established:''' 1964 by [[Dr. Irving Selikoff]] (Mount Sinai)
	* '''OSHA Established:''' 1970 (influenced by Selikoff's research)		* '''OSHA Established:''' 1970 (influenced by Selikoff's research)
	* '''First Staging System:''' 1976 by Dr. Eric Butchart		* '''First Staging System:''' 1976 by Dr. Eric Butchart
	* '''International Mesothelioma Program Founded:''' 2002 by Dr. David Sugarbaker		* '''International Mesothelioma Program Founded:''' 2002 by [[Dr. David Sugarbaker]]
	* '''First FDA-Approved Chemotherapy:''' February 4, 2004 (pemetrexed + cisplatin)		* '''First FDA-Approved Chemotherapy:''' February 4, 2004 (pemetrexed + cisplatin)
	* '''Tumor Treating Fields Approved:''' May 2019 (Optune Lua)		* '''Tumor Treating Fields Approved:''' May 2019 (Optune Lua)
Line 74:		Line 74:
	\| style="padding:10px; font-weight:bold;" \| 1843		\| style="padding:10px; font-weight:bold;" \| 1843
	\| style="padding:10px;" \| Karl von Rokitansky identifies peritoneal tumors		\| style="padding:10px;" \| Karl von Rokitansky identifies peritoneal tumors
	\| style="padding:10px;" \| Early peritoneal mesothelioma recognition		\| style="padding:10px;" \| Early [[Peritoneal Mesothelioma\|peritoneal mesothelioma]] recognition
	\|-		\|-
	\| style="padding:10px; font-weight:bold;" \| 1870		\| style="padding:10px; font-weight:bold;" \| 1870
Line 99:		Line 99:
	{\| style="width:100%; border:1px solid #007bff; border-left:5px solid #007bff; border-radius:4px; margin:1em 0;"		{\| style="width:100%; border:1px solid #007bff; border-left:5px solid #007bff; border-radius:4px; margin:1em 0;"
	\|-		\|-
	\| style="padding:15px; " \| '''ℹ️ The Missing Link:''' Despite widespread industrial asbestos use during this period, the connection between asbestos exposure and mesothelioma remained unknown. Millions of workers were exposed without any understanding of the deadly consequences.		\| style="padding:15px; " \| '''ℹ️ The Missing Link:''' Despite widespread industrial asbestos use during this period, the connection between [[Asbestos Exposure\|asbestos exposure]] and mesothelioma remained unknown. Millions of workers were exposed without any understanding of the deadly consequences.
	\|}		\|}

Line 231:		Line 231:
	\| style="padding:10px; font-weight:bold; " \| Oct 2, 2020		\| style="padding:10px; font-weight:bold; " \| Oct 2, 2020
	\| style="padding:10px; " \| '''FDA approves nivolumab + ipilimumab ([[CheckMate_743_Trial\|CheckMate 743]])'''		\| style="padding:10px; " \| '''FDA approves nivolumab + ipilimumab ([[CheckMate_743_Trial\|CheckMate 743]])'''
	\| style="padding:10px; " \| '''First immunotherapy for mesothelioma<ref>[https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-and-ipilimumab-unresectable-malignant-pleural-mesothelioma FDA Approves Nivolumab and Ipilimumab for Mesothelioma], U.S. Food and Drug Administration</ref>'''		\| style="padding:10px; " \| '''First [[Immunotherapy for Mesothelioma\|immunotherapy for mesothelioma]]<ref>[https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-and-ipilimumab-unresectable-malignant-pleural-mesothelioma FDA Approves Nivolumab and Ipilimumab for Mesothelioma], U.S. Food and Drug Administration</ref>'''
	\|-		\|-
	\| style="padding:10px; font-weight:bold;" \| Jan 2021		\| style="padding:10px; font-weight:bold;" \| Jan 2021

← Older revision		Revision as of 03:01, 29 January 2026
Line 7:		Line 7:
	\|published_time=2026-01-28		\|published_time=2026-01-28
	}}		}}
	{\| class="infobox" style="width:280px; float:right; margin:0 0 1em 1em; border:2px solid #1a5276; background:#ffffff; border-radius:8px; overflow:hidden;"		{\| class="infobox" style="width:280px; float:right; margin:0 0 1em 1em; border:2px solid #1a5276; background:#ffffff; color:#333333; border-radius:8px; overflow:hidden;"
	\|-		\|-
	! colspan="2" style="background:#1a5276; color:white; padding:12px; font-size:1.1em; text-align:center;" \| Mesothelioma Timeline at a Glance		! colspan="2" style="background:#1a5276; color:white; padding:12px; font-size:1.1em; text-align:center;" \| Mesothelioma Timeline at a Glance
	\|-		\|-
	\| colspan="2" style="background:#e8f4f8; padding:10px; text-align:center; font-style:italic;" \| 250+ Years of Scientific Progress		\| colspan="2" style="background:#e8f4f8; color:#333333; padding:10px; text-align:center; font-style:italic;" \| 250+ Years of Scientific Progress
	\|-		\|-
	\| style="padding:10px; font-weight:bold; width:40%; background:#f8f9fa; border-bottom:1px solid #dee2e6;" \| First Cases		\| style="padding:10px; font-weight:bold; width:40%; background:#f8f9fa; color:#333333; border-bottom:1px solid #dee2e6;" \| First Cases
	\| style="padding:10px; border-bottom:1px solid #dee2e6;" \| 1767		\| style="padding:10px; border-bottom:1px solid #dee2e6;" \| 1767
	\|-		\|-
	\| style="padding:10px; font-weight:bold; background:#f8f9fa; border-bottom:1px solid #dee2e6;" \| Disease Named		\| style="padding:10px; font-weight:bold; background:#f8f9fa; color:#333333; border-bottom:1px solid #dee2e6;" \| Disease Named
	\| style="padding:10px; border-bottom:1px solid #dee2e6;" \| 1909		\| style="padding:10px; border-bottom:1px solid #dee2e6;" \| 1909
	\|-		\|-
	\| style="padding:10px; font-weight:bold; background:#f8f9fa; border-bottom:1px solid #dee2e6;" \| Asbestos Link		\| style="padding:10px; font-weight:bold; background:#f8f9fa; color:#333333; border-bottom:1px solid #dee2e6;" \| Asbestos Link
	\| style="padding:10px; border-bottom:1px solid #dee2e6;" \| 1960		\| style="padding:10px; border-bottom:1px solid #dee2e6;" \| 1960
	\|-		\|-
	\| style="padding:10px; font-weight:bold; background:#f8f9fa; border-bottom:1px solid #dee2e6;" \| OSHA Created		\| style="padding:10px; font-weight:bold; background:#f8f9fa; color:#333333; border-bottom:1px solid #dee2e6;" \| OSHA Created
	\| style="padding:10px; border-bottom:1px solid #dee2e6;" \| 1970		\| style="padding:10px; border-bottom:1px solid #dee2e6;" \| 1970
	\|-		\|-
	\| style="padding:10px; font-weight:bold; background:#f8f9fa; border-bottom:1px solid #dee2e6;" \| First Chemo		\| style="padding:10px; font-weight:bold; background:#f8f9fa; color:#333333; border-bottom:1px solid #dee2e6;" \| First Chemo
	\| style="padding:10px; border-bottom:1px solid #dee2e6;" \| 2004		\| style="padding:10px; border-bottom:1px solid #dee2e6;" \| 2004
	\|-		\|-
	\| style="padding:10px; font-weight:bold; background:#f8f9fa;" \| Immunotherapy		\| style="padding:10px; font-weight:bold; background:#f8f9fa; color:#333333;" \| Immunotherapy
	\| style="padding:10px;" \| 2020		\| style="padding:10px;" \| 2020
	\|-		\|-
Line 44:		Line 44:
	! style="background:#1a5276; color:white; padding:12px; text-align:left;" \| Key Facts: Mesothelioma Treatment Milestones		! style="background:#1a5276; color:white; padding:12px; text-align:left;" \| Key Facts: Mesothelioma Treatment Milestones
	\|-		\|-
	\| style="padding:15px; background:#f8f9fa;" \|		\| style="padding:15px; background:#f8f9fa; color:#333333;" \|
	* '''First Documented Cases:''' 1767 by Joseph Lieutaud (France)		* '''First Documented Cases:''' 1767 by Joseph Lieutaud (France)
	* '''Disease Named "Mesothelioma":''' 1909 by J.G. Adami (UK)		* '''Disease Named "Mesothelioma":''' 1909 by J.G. Adami (UK)
Line 137:		Line 137:
	\|}		\|}

	{\| style="width:95%; margin:1em auto; background:#f8f9fa; border-left:4px solid #1a5276; border-radius:4px;"		{\| style="width:95%; margin:1em auto; background:#f8f9fa; color:#333333; border-left:4px solid #1a5276; border-radius:4px;"
	\|-		\|-
	\| style="padding:15px 20px 10px; font-style:italic; font-size:1.05em; line-height:1.5;" \| "The 1960s represented a turning point in mesothelioma history. Wagner and Selikoff's research proved what asbestos companies had hidden for decades: their products were killing workers. That evidence forms the foundation for the legal cases we pursue today."		\| style="padding:15px 20px 10px; font-style:italic; font-size:1.05em; line-height:1.5;" \| "The 1960s represented a turning point in mesothelioma history. Wagner and Selikoff's research proved what asbestos companies had hidden for decades: their products were killing workers. That evidence forms the foundation for the legal cases we pursue today."
Line 263:		Line 263:
	\|}		\|}

	{\| style="width:95%; margin:1em auto; background:#f8f9fa; border-left:4px solid #1a5276; border-radius:4px;"		{\| style="width:95%; margin:1em auto; background:#f8f9fa; color:#333333; border-left:4px solid #1a5276; border-radius:4px;"
	\|-		\|-
	\| style="padding:15px 20px 10px; font-style:italic; font-size:1.05em; line-height:1.5;" \| "October 2, 2020 was a watershed moment for mesothelioma patients. For the first time in 16 years, we could tell newly diagnosed clients about a fundamentally new treatment option—one that offered real hope, especially for those with non-epithelioid disease who previously had so few options."		\| style="padding:15px 20px 10px; font-style:italic; font-size:1.05em; line-height:1.5;" \| "October 2, 2020 was a watershed moment for mesothelioma patients. For the first time in 16 years, we could tell newly diagnosed clients about a fundamentally new treatment option—one that offered real hope, especially for those with non-epithelioid disease who previously had so few options."
Line 338:		Line 338:
	\|}		\|}

	{\| style="width:95%; margin:1em auto; background:#f8f9fa; border-left:4px solid #1a5276; border-radius:4px;"		{\| style="width:95%; margin:1em auto; background:#f8f9fa; color:#333333; border-left:4px solid #1a5276; border-radius:4px;"
	\|-		\|-
	\| style="padding:15px 20px 10px; font-style:italic; font-size:1.05em; line-height:1.5;" \| "Looking at this timeline, the progress is remarkable. A diagnosis that once meant months to live can now mean years with modern treatment. And the pace of research is accelerating—the breakthroughs of the next decade will likely exceed everything that came before."		\| style="padding:15px 20px 10px; font-style:italic; font-size:1.05em; line-height:1.5;" \| "Looking at this timeline, the progress is remarkable. A diagnosis that once meant months to live can now mean years with modern treatment. And the pace of research is accelerating—the breakthroughs of the next decade will likely exceed everything that came before."